The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.
 
Bruno Vincenzi
Speakers' Bureau - PharmaMar
 
Andrea Napolitano
Travel, Accommodations, Expenses - PharmaMar
 
Margherita Nannini
Travel, Accommodations, Expenses - PharmaMar
 
Elena Fumagalli
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; PharmaMar
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar; tesaro
 
Javier Martin Broto
Honoraria - Bayer; Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Nadia Hindi
Honoraria - Lilly; PharmaMar
Research Funding - Amgen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Lilly; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Peter Hohenberger
Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Roche
Consulting or Advisory Role - Lilly; Nanobiotix; Pfizer
Research Funding - Novartis; Siemens Healthcare Diagnostics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Antonella Brunello
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Ipsen; PharmaMar; Takeda
 
Silvia Gasperoni
No Relationships to Disclose
 
Heikki Joensuu
Employment - Orion
Leadership - Sartar Therapeutics
Stock and Other Ownership Interests - Faron Pharmaceuticals; Orion
Consulting or Advisory Role - Neutron Therapeutics
Patents, Royalties, Other Intellectual Property - Sartar Therapeutics
 
Giuseppe Badalamenti
No Relationships to Disclose
 
Spyridon Gennatas
No Relationships to Disclose
 
Tommaso Martino De Pas
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Angelo Paolo Dei Tos
Honoraria - PharmaMar
Research Funding - PharmaMar
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Sebastian Bauer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Bayer; Blueprint Medicines; Daiichi Sankyo; Deciphera; Exelixis; Janssen-Cilag; Janssen-Cilag; Lilly; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar